Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2018
Endolaserless Vitrectomy with Intravitreal Aflibercept
Dennis M. Marcus, MD
Updates from the Field
2017
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019

Category: AMD-Neovascular

See more